Indraprastha Medical Corporation Limited INDRAMEDCO NSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.apollohospitals.com/delhi/

Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.

Market & Price

Market Cap

₹3,486.78 Cr

Current Price

₹380.35

High / Low (52W)

₹622.80 / ₹349.50

Beta

0.52

Valuation

Stock P/E

18.98

Industry PE

37.60

Forward P/E

15.46

PEG Ratio

Book Value

₹71.88

Price to Book

5.29

P/S

2.35

EV/EBITDA

12.21

Dividend Yield

1.18%

Profitability & Returns

ROCE

30.67%

ROE

27.47%

ROA

15.15%

Profit Margin

12.39%

Op Margin

13.48%

EPS (Latest Qtr)

₹4.55

EPS (TTM)

₹20.04

Balance Sheet & Liquidity

Debt/Equity

4.98

Quick Ratio

2.27

Current Ratio

2.46

Debt

₹36.86 Cr

Total Assets

₹991.36 Cr

Current Assets

₹416.59 Cr

Working Capital

₹247.04 Cr

Ownership

Promoter Holding

55.39%

Chg in Prom Hold

FII / Inst Holding

0.59%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹3,259.41 Cr

Total Revenue (TTM)

₹1,482.51 Cr

EBITDA

₹266.92 Cr

Free Cash Flow

₹68.40 Cr

Operating Cash Flow

₹167.44 Cr

Shares Outstanding

₹9.17 Cr

Gross Margin

37.04%

Payout Ratio

22.47%

Growth (CAGR)

Revenue 5Y

11.66%

Profit 5Y

28.69%

Revenue (YoY)

9.30%

Earnings (YoY)

1.80%

PROS

Strong return on equity of 27.5%.
Healthy ROCE of 30.7%.
Compounding revenue at 11.7% over 5 years.
Profit CAGR of 28.7% over 5 years.
Generates positive free cash flow.

CONS

Trading 38.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INDRAMEDCO Indraprastha Medical Corporation Limited NSEPHARMA	380.35	18.98	₹3,486.78 Cr	1.18%	30.67%	27.47%	11.66%	28.69%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	324.93 Cr	333.75 Cr	365.06 Cr	371.61 Cr	364.81 Cr
Cost of Revenue	214.40 Cr	213.15 Cr	225.63 Cr	234.10 Cr	235.07 Cr
Gross Profit	110.53 Cr	120.60 Cr	139.43 Cr	137.51 Cr	129.74 Cr
Operating Expenses	69.55 Cr	70.19 Cr	76.46 Cr	86.81 Cr	80.57 Cr
Operating Income	40.98 Cr	50.41 Cr	62.97 Cr	50.70 Cr	49.17 Cr
EBITDA	57.32 Cr	67.67 Cr	80.05 Cr	69.10 Cr	67.84 Cr
Interest Expense	1.58 Cr	1.49 Cr	1.56 Cr	1.46 Cr	1.49 Cr
Pretax Income	44.53 Cr	55.27 Cr	68.31 Cr	56.39 Cr	55.01 Cr
Tax Provision	11.72 Cr	14.26 Cr	16.85 Cr	15.39 Cr	13.31 Cr
Net Income	32.81 Cr	41.01 Cr	51.46 Cr	41.00 Cr	41.70 Cr
Diluted EPS	3.58	4.47	5.61	4.47	4.55

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,064.95 Cr	1,204.06 Cr	1,356.36 Cr	1,482.51 Cr
Cost of Revenue	-	720.30 Cr	780.96 Cr	862.74 Cr	933.33 Cr
Gross Profit	-	344.65 Cr	423.10 Cr	493.62 Cr	549.18 Cr
Operating Expenses	-	232.35 Cr	259.02 Cr	293.68 Cr	325.89 Cr
Operating Income	-	112.30 Cr	164.08 Cr	199.94 Cr	223.29 Cr
EBITDA	-	156.91 Cr	207.25 Cr	266.92 Cr	295.67 Cr
Interest Expense	-	46.00 L	1.06 Cr	6.27 Cr	6.02 Cr
Pretax Income	-	117.18 Cr	166.11 Cr	216.32 Cr	246.02 Cr
Tax Provision	-	31.03 Cr	42.15 Cr	55.33 Cr	62.40 Cr
Net Income	-	86.15 Cr	123.96 Cr	160.99 Cr	183.62 Cr
Diluted EPS	-	9.40	13.52	17.56	20.03

Compounded Sales Growth

5 Years:	11.66%
1 Year:	9.30%

Compounded Profit Growth

5 Years:	28.69%
1 Year:	1.80%

Stock Price Performance

1 Year:	-14.42%
6 Months:	-24.94%
3 Months:	-5.22%
1 Month:	-5.40%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	555.14 Cr	723.24 Cr	851.62 Cr	991.36 Cr
Current Assets	-	223.08 Cr	307.98 Cr	431.13 Cr	416.59 Cr
Cash & Equivalents	-	52.26 Cr	61.60 Cr	61.48 Cr	4.93 Cr
Inventory	-	8.45 Cr	7.53 Cr	6.99 Cr	7.86 Cr
Receivables	-	68.24 Cr	58.40 Cr	75.45 Cr	112.16 Cr
Total Liabilities	-	175.69 Cr	245.48 Cr	254.94 Cr	250.99 Cr
Current Liabilities	-	129.63 Cr	165.42 Cr	178.71 Cr	169.55 Cr
Long Term Debt	-	-	-	-	-
Total Debt	-	2.48 Cr	33.95 Cr	32.76 Cr	36.86 Cr
Total Equity	-	379.45 Cr	477.76 Cr	596.68 Cr	740.37 Cr
Shares Outstanding	-	9.17 Cr	9.17 Cr	9.17 Cr	9.17 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	144.47 Cr	200.15 Cr	156.75 Cr	167.44 Cr
Investing Cash Flow	-	-107.91 Cr	-158.43 Cr	-110.99 Cr	-177.61 Cr
Financing Cash Flow	-	-26.04 Cr	-32.38 Cr	-45.88 Cr	-46.38 Cr
Capital Expenditure	-	-44.58 Cr	-69.39 Cr	-36.33 Cr	-59.65 Cr
Free Cash Flow	-	99.89 Cr	130.76 Cr	120.42 Cr	107.79 Cr
Net Change in Cash	-	10.52 Cr	9.34 Cr	-12.00 L	-56.55 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	32.4%	35.1%	36.4%	37.0%
Operating Margin %	-	10.5%	13.6%	14.7%	15.1%
Net Margin %	-	8.1%	10.3%	11.9%	12.4%
ROE %	-	22.7%	25.9%	27.0%	24.8%
ROCE %	-	26.4%	29.4%	29.7%	27.2%

Shareholding Pattern

Insiders

55.39%

Institutions

0.59%

Public Float

1.32%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDRAMEDCO

No recent headlines available.

INDRAMEDCO · Healthcare